BACKGROUND: While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term outcome in matched (MUD) and mismatched unrelated donor (mMUD) setting is not well defined. METHODS: Herein, we evaluated a consecutive case-series of 482 patients who underwent unrelated donor HCT (2005-2013) with T/S-based GvHD prophylaxis. RESULTS: With a median follow-up of 6.2 years (range = 2.4-11.3), the 5-year overall survival (OS) and relapse/progression-free survival were 47.5% (95% confidence interval [CI]: 43.0-52.0) and 43.6% (95% CI: 39.1-48.1), respectively; and the 5-year cumulative incidence of nonrelapse mortality (NRM) and relapse were 24.9%, and 31.5%, respectively. In this cohort, mMUD was associated with worse OS (39.0% versus 50.7% at 5 y; P = 0.034), primarily due to greater risk of NRM (33.5% versus 21.7%; P = 0.038). While rates of relapse, acute (II-IV or III-IV) or chronic GvHD (limited or extensive) were not different, death caused by chronic GvHD (20.8% versus 12.8%; P = 0.022) and infection (33.0% versus 18.1%; P < 0.01) were significantly greater in mMUD. In multivariable analysis, high-risk disease (hazard ratio [HR] = 2.21, 95% CI: 1.16-4.23; P < 0.01) and mMUD (HR = 1.55, 95% CI: 1.15-2.08; P = 0.004) were independent predictive factors for OS. CONCLUSIONS: T/S-based GvHD prophylaxis is an effective and acceptable GvHD prophylactic regimen. However, survival after mMUD remained poor, possibly related to the severity of chronic GvHD.
BACKGROUND: While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term outcome in matched (MUD) and mismatched unrelated donor (mMUD) setting is not well defined. METHODS: Herein, we evaluated a consecutive case-series of 482 patients who underwent unrelated donor HCT (2005-2013) with T/S-based GvHD prophylaxis. RESULTS: With a median follow-up of 6.2 years (range = 2.4-11.3), the 5-year overall survival (OS) and relapse/progression-free survival were 47.5% (95% confidence interval [CI]: 43.0-52.0) and 43.6% (95% CI: 39.1-48.1), respectively; and the 5-year cumulative incidence of nonrelapse mortality (NRM) and relapse were 24.9%, and 31.5%, respectively. In this cohort, mMUD was associated with worse OS (39.0% versus 50.7% at 5 y; P = 0.034), primarily due to greater risk of NRM (33.5% versus 21.7%; P = 0.038). While rates of relapse, acute (II-IV or III-IV) or chronic GvHD (limited or extensive) were not different, death caused by chronic GvHD (20.8% versus 12.8%; P = 0.022) and infection (33.0% versus 18.1%; P < 0.01) were significantly greater in mMUD. In multivariable analysis, high-risk disease (hazard ratio [HR] = 2.21, 95% CI: 1.16-4.23; P < 0.01) and mMUD (HR = 1.55, 95% CI: 1.15-2.08; P = 0.004) were independent predictive factors for OS. CONCLUSIONS: T/S-based GvHD prophylaxis is an effective and acceptable GvHD prophylactic regimen. However, survival after mMUD remained poor, possibly related to the severity of chronic GvHD.
Authors: Corey Cutler; Brent Logan; Ryotaro Nakamura; Laura Johnston; Sung Choi; David Porter; William J Hogan; Marcelo Pasquini; Margaret L MacMillan; Jack W Hsu; Edmund K Waller; Stephan Grupp; Philip McCarthy; Juan Wu; Zhen-Huan Hu; Shelly L Carter; Mary M Horowitz; Joseph H Antin Journal: Blood Date: 2014-06-30 Impact factor: 22.113
Authors: R Parody; L Lopez-Corral; O L Godino; I G Cadenas; A P Martinez; L Vazquez; R Martino; C Martinez; C Solano; P Barba; D Valcarcel; T Caballero-Velazquez; F J Marquez-Malaver; J Sierra; D Caballero; J A Perez-Simón Journal: Bone Marrow Transplant Date: 2014-10-13 Impact factor: 5.483
Authors: Joseph Pidala; Jongphil Kim; Heather Jim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Hugo F Fernandez; Marcie Tomblyn; Lia Perez; Janelle Perkins; Mian Xu; William E Janssen; Anandaraman Veerapathran; Brian C Betts; Frederick L Locke; Ernesto Ayala; Teresa Field; Leonel Ochoa; Melissa Alsina; Claudio Anasetti Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941
Authors: Corey Cutler; Shuli Li; Vincent T Ho; John Koreth; Edwin Alyea; Robert J Soiffer; Joseph H Antin Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman Journal: Blood Date: 2009-11-19 Impact factor: 22.113
Authors: Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf Journal: Blood Date: 2004-06-10 Impact factor: 22.113
Authors: Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber Journal: Blood Date: 2014-04-17 Impact factor: 22.113
Authors: S K Khaled; J Palmer; T Stiller; D Senitzer; R Maegawa; R Rodriguez; P M Parker; A Nademanee; J L Cai; D S Snyder; C Karanes; E Osorio; S H Thomas; S J Forman; R Nakamura Journal: Bone Marrow Transplant Date: 2012-09-24 Impact factor: 5.483
Authors: Shernan G Holtan; Jingbo Yu; Dilan Paranagama; Jackson Tang; Hannah K Choe; Ahmad Naim; H Joachim Deeg; John Galvin Journal: Bone Marrow Transplant Date: 2022-06-23 Impact factor: 5.174